FDA approves Tafinlar-Mekinist combination for adjuvant treatment of BRAF-mutant melanoma

The FDA approved the combination of dabrafenib and trametinib for adjuvant treatment of patients with BRAF V600E- or BRAF V600K-positive melanoma that has spread to their lymph nodes.

Read the full story

Posted in Melanoma In The News, FDA

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

The US Food and Drug Administration (FDA) approved dabrafenib with trametinib as an adjuvant therapy following complete resection for patients with BRAFV600E- or V600K-mutated melanoma with lymph node involvement, according to a press release.1

Read the full story

Posted in Melanoma In The News, FDA

FDA Approves Opdivo For Resected Melanoma

The FDA approved nivolumab injection for the adjuvant treatment of patients with melanoma who have involved lymph nodes or metastatic disease and who underwent complete resection.

Read the full story

Posted in Melanoma In The News, FDA

FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF + Melanoma

The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of dabrafenib (Tafinlar) combined with trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Read the full story

Posted in Melanoma In The News, FDA

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories